Cargando…

The Mechanism Actions of Astragaloside IV Prevents the Progression of Hypertensive Heart Disease Based on Network Pharmacology and Experimental Pharmacology

Astragaloside IV (AS-IV) has been used to treat cardiovascular disease. However, whether AS-IV exerts a protective effect against hypertensive heart disease has not been investigated. This study aimed to investigate the antihypertensive and cardioprotective effects of AS-IV on L-NAME-induced hyperte...

Descripción completa

Detalles Bibliográficos
Autores principales: Jing, Haoran, Xie, Rongsheng, Bai, Yu, Duan, Yuchen, Sun, Chongyang, Wang, Ye, Cao, Rongyi, Ling, Zaisheng, Qu, Xiufen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602690/
https://www.ncbi.nlm.nih.gov/pubmed/34803698
http://dx.doi.org/10.3389/fphar.2021.755653
_version_ 1784601623675273216
author Jing, Haoran
Xie, Rongsheng
Bai, Yu
Duan, Yuchen
Sun, Chongyang
Wang, Ye
Cao, Rongyi
Ling, Zaisheng
Qu, Xiufen
author_facet Jing, Haoran
Xie, Rongsheng
Bai, Yu
Duan, Yuchen
Sun, Chongyang
Wang, Ye
Cao, Rongyi
Ling, Zaisheng
Qu, Xiufen
author_sort Jing, Haoran
collection PubMed
description Astragaloside IV (AS-IV) has been used to treat cardiovascular disease. However, whether AS-IV exerts a protective effect against hypertensive heart disease has not been investigated. This study aimed to investigate the antihypertensive and cardioprotective effects of AS-IV on L-NAME-induced hypertensive rats via network pharmacology and experimental pharmacology. The network pharmacology and bioinformatics analyses were performed to obtain the potential targets of AS-IV and hypertensive heart disease. The rat hypertension model was established by administrated 50 mg/kg/day of L-NAME for 5 weeks. Meanwhile, hypertension rats were intragastrically administrated with vehicle or AS-IV or fosinopril for 5 weeks. Cardiovascular parameters (systolic blood pressure, diastolic blood pressure, mean arterial pressure, heart rates, and body weight), cardiac function parameters (LVEDd, LVEDs, and fractional shortening), cardiac marker enzymes (creatine kinase, CK-MB, and lactate dehydrogenase), cardiac hypertrophy markers (atrial natriuretic peptide and brain natriuretic peptide), endothelial function biomarkers (nitric oxide and eNOS), inflammation biomarkers (IL-6 and TNF-α) and oxidative stress biomarkers (SOD, MDA, and GSH) were measured and cardiac tissue histology performed. Network pharmacological analysis screened the top 20 key genes in the treatment of hypertensive heart disease treated with AS-IV. Besides, AS-IV exerted a beneficial effect on cardiovascular and cardiac function parameters. Moreover, AS-IV alleviated cardiac hypertrophy via down-regulating the expression of ANP and BNP and improved histopathology changes of cardiac tissue. AS-IV improved endothelial function via the up-regulation of eNOS expression, alleviated oxidative stress via increasing antioxidant enzymes activities, and inhibited cardiac inflammation via down-regulating IL-6 and TNF-α expression. Our findings suggested that AS-IV is a potential therapeutic drug to improve L-NAME-induced hypertensive heart disease partly mediated via modulation of eNOS and oxidative stress.
format Online
Article
Text
id pubmed-8602690
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86026902021-11-20 The Mechanism Actions of Astragaloside IV Prevents the Progression of Hypertensive Heart Disease Based on Network Pharmacology and Experimental Pharmacology Jing, Haoran Xie, Rongsheng Bai, Yu Duan, Yuchen Sun, Chongyang Wang, Ye Cao, Rongyi Ling, Zaisheng Qu, Xiufen Front Pharmacol Pharmacology Astragaloside IV (AS-IV) has been used to treat cardiovascular disease. However, whether AS-IV exerts a protective effect against hypertensive heart disease has not been investigated. This study aimed to investigate the antihypertensive and cardioprotective effects of AS-IV on L-NAME-induced hypertensive rats via network pharmacology and experimental pharmacology. The network pharmacology and bioinformatics analyses were performed to obtain the potential targets of AS-IV and hypertensive heart disease. The rat hypertension model was established by administrated 50 mg/kg/day of L-NAME for 5 weeks. Meanwhile, hypertension rats were intragastrically administrated with vehicle or AS-IV or fosinopril for 5 weeks. Cardiovascular parameters (systolic blood pressure, diastolic blood pressure, mean arterial pressure, heart rates, and body weight), cardiac function parameters (LVEDd, LVEDs, and fractional shortening), cardiac marker enzymes (creatine kinase, CK-MB, and lactate dehydrogenase), cardiac hypertrophy markers (atrial natriuretic peptide and brain natriuretic peptide), endothelial function biomarkers (nitric oxide and eNOS), inflammation biomarkers (IL-6 and TNF-α) and oxidative stress biomarkers (SOD, MDA, and GSH) were measured and cardiac tissue histology performed. Network pharmacological analysis screened the top 20 key genes in the treatment of hypertensive heart disease treated with AS-IV. Besides, AS-IV exerted a beneficial effect on cardiovascular and cardiac function parameters. Moreover, AS-IV alleviated cardiac hypertrophy via down-regulating the expression of ANP and BNP and improved histopathology changes of cardiac tissue. AS-IV improved endothelial function via the up-regulation of eNOS expression, alleviated oxidative stress via increasing antioxidant enzymes activities, and inhibited cardiac inflammation via down-regulating IL-6 and TNF-α expression. Our findings suggested that AS-IV is a potential therapeutic drug to improve L-NAME-induced hypertensive heart disease partly mediated via modulation of eNOS and oxidative stress. Frontiers Media S.A. 2021-11-05 /pmc/articles/PMC8602690/ /pubmed/34803698 http://dx.doi.org/10.3389/fphar.2021.755653 Text en Copyright © 2021 Jing, Xie, Bai, Duan, Sun, Wang, Cao, Ling and Qu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Jing, Haoran
Xie, Rongsheng
Bai, Yu
Duan, Yuchen
Sun, Chongyang
Wang, Ye
Cao, Rongyi
Ling, Zaisheng
Qu, Xiufen
The Mechanism Actions of Astragaloside IV Prevents the Progression of Hypertensive Heart Disease Based on Network Pharmacology and Experimental Pharmacology
title The Mechanism Actions of Astragaloside IV Prevents the Progression of Hypertensive Heart Disease Based on Network Pharmacology and Experimental Pharmacology
title_full The Mechanism Actions of Astragaloside IV Prevents the Progression of Hypertensive Heart Disease Based on Network Pharmacology and Experimental Pharmacology
title_fullStr The Mechanism Actions of Astragaloside IV Prevents the Progression of Hypertensive Heart Disease Based on Network Pharmacology and Experimental Pharmacology
title_full_unstemmed The Mechanism Actions of Astragaloside IV Prevents the Progression of Hypertensive Heart Disease Based on Network Pharmacology and Experimental Pharmacology
title_short The Mechanism Actions of Astragaloside IV Prevents the Progression of Hypertensive Heart Disease Based on Network Pharmacology and Experimental Pharmacology
title_sort mechanism actions of astragaloside iv prevents the progression of hypertensive heart disease based on network pharmacology and experimental pharmacology
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602690/
https://www.ncbi.nlm.nih.gov/pubmed/34803698
http://dx.doi.org/10.3389/fphar.2021.755653
work_keys_str_mv AT jinghaoran themechanismactionsofastragalosideivpreventstheprogressionofhypertensiveheartdiseasebasedonnetworkpharmacologyandexperimentalpharmacology
AT xierongsheng themechanismactionsofastragalosideivpreventstheprogressionofhypertensiveheartdiseasebasedonnetworkpharmacologyandexperimentalpharmacology
AT baiyu themechanismactionsofastragalosideivpreventstheprogressionofhypertensiveheartdiseasebasedonnetworkpharmacologyandexperimentalpharmacology
AT duanyuchen themechanismactionsofastragalosideivpreventstheprogressionofhypertensiveheartdiseasebasedonnetworkpharmacologyandexperimentalpharmacology
AT sunchongyang themechanismactionsofastragalosideivpreventstheprogressionofhypertensiveheartdiseasebasedonnetworkpharmacologyandexperimentalpharmacology
AT wangye themechanismactionsofastragalosideivpreventstheprogressionofhypertensiveheartdiseasebasedonnetworkpharmacologyandexperimentalpharmacology
AT caorongyi themechanismactionsofastragalosideivpreventstheprogressionofhypertensiveheartdiseasebasedonnetworkpharmacologyandexperimentalpharmacology
AT lingzaisheng themechanismactionsofastragalosideivpreventstheprogressionofhypertensiveheartdiseasebasedonnetworkpharmacologyandexperimentalpharmacology
AT quxiufen themechanismactionsofastragalosideivpreventstheprogressionofhypertensiveheartdiseasebasedonnetworkpharmacologyandexperimentalpharmacology
AT jinghaoran mechanismactionsofastragalosideivpreventstheprogressionofhypertensiveheartdiseasebasedonnetworkpharmacologyandexperimentalpharmacology
AT xierongsheng mechanismactionsofastragalosideivpreventstheprogressionofhypertensiveheartdiseasebasedonnetworkpharmacologyandexperimentalpharmacology
AT baiyu mechanismactionsofastragalosideivpreventstheprogressionofhypertensiveheartdiseasebasedonnetworkpharmacologyandexperimentalpharmacology
AT duanyuchen mechanismactionsofastragalosideivpreventstheprogressionofhypertensiveheartdiseasebasedonnetworkpharmacologyandexperimentalpharmacology
AT sunchongyang mechanismactionsofastragalosideivpreventstheprogressionofhypertensiveheartdiseasebasedonnetworkpharmacologyandexperimentalpharmacology
AT wangye mechanismactionsofastragalosideivpreventstheprogressionofhypertensiveheartdiseasebasedonnetworkpharmacologyandexperimentalpharmacology
AT caorongyi mechanismactionsofastragalosideivpreventstheprogressionofhypertensiveheartdiseasebasedonnetworkpharmacologyandexperimentalpharmacology
AT lingzaisheng mechanismactionsofastragalosideivpreventstheprogressionofhypertensiveheartdiseasebasedonnetworkpharmacologyandexperimentalpharmacology
AT quxiufen mechanismactionsofastragalosideivpreventstheprogressionofhypertensiveheartdiseasebasedonnetworkpharmacologyandexperimentalpharmacology